Chemomab Therapeutics
ChemomAb Therapeutics Ltd, based in Tel Aviv, Israel, is a clinical-stage biopharmaceutical company founded in 2011. The company specializes in developing proprietary monoclonal antibodies aimed at treating autoimmune and inflammatory diseases, particularly focusing on fibrotic disorders with significant unmet medical needs. Its lead candidate, CM-101, targets CCL24 and has shown promising safety and efficacy through pre-clinical studies and ongoing clinical trials. CM-101 operates through a novel mechanism of action that interferes with the biology of fibrosis in the liver, skin, and lungs. Currently, ChemomAb is advancing three Phase 2 clinical trials for CM-101, addressing severe and life-threatening fibrotic conditions as well as other immune-mediated diseases.
Anchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/ß-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/ß-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/ß-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.